ArticleCancer research2010
Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 41 citations in OpenAlex.
- The PELP1 Pathway and Its Importance in Cancer Treatment.Biomolecules · 2025Review
- Proline-, Glutamic Acid-, Leucine-Rich Protein 1 (PELP1): Diversity, Structural Conservation, and Evolutionary Origins Across the Species.International journal of molecular sciences · 2025Article
- Non-apoptotic regulated cell death based prognostic risk model for colorectal cancer using machine learning guided two-step framework.Briefings in bioinformatics · 2025Article
- Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.Breast cancer research and treatment · 2023Article
- Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold.Nature communications · 2022Article
- A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.Cancer research · 2022Article
- Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC.Cancers · 2022Article
- PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant EROncogene · 2021Article
- Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.Molecular oncology · 2021Article
- Role of estrogen receptor coregulators in endocrine resistant breast cancer.Exploration of targeted anti-tumor therapy · 2021Article
- Overexpression of PELP1 in Lung Adenocarcinoma Promoted EPathology oncology research : POR · 2021Article
- PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer.Oncotarget · 2020Article
- Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.Breast cancer research : BCR · 2019Article
- PELP1: a key mediator of oestrogen signalling and actions in the brain.Journal of neuroendocrinology · 2018Review
- Structural prediction of the interaction of the tumor suppressor p27BMC bioinformatics · 2017Article
- Review
- Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.BMC cancer · 2015Article
- Minireview: Deciphering the Cellular Functions of PELP1.Molecular endocrinology (Baltimore, Md.) · 2015Review
- Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.Breast cancer research and treatment · 2015Article
- PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.Cancer research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Estrogen receptor (ER) signaling plays an important role in breast cancer progression, and ER functions are influenced by coregulatory proteins. PELP1 (proline-, glutamic acid-, and leucine-rich protein 1) is a nuclear receptor coregulator that plays an important role in ER signaling. Its expression is deregulated in hormonal cancers. We identified PELP1 as a novel cyclin-dependent kinase (CDK) substrate. Using site-directed mutagenesis and in vitro kinase assays, we identified Ser(477) and Ser(991) of PELP1 as CDK phosphorylation sites. Using the PELP1 Ser(991) phospho-specific antibody, we show that PELP1 is hyperphosphorylated during cell cycle progression. Model cells stably expressing the PELP1 mutant that lack CDK sites had defects in estradiol (E2)-mediated cell cycle progression and significantly affected PELP1-mediated oncogenic functions in vivo. Mechanistic studies showed that PELP1 modulates transcription factor E2F1 transactivation functions, that PELP1 is recruited to pRb/E2F target genes, and that PELP1 facilitates ER signaling cross talk with cell cycle machinery. We conclude that PELP1 is a novel substrate of interphase CDKs and that its phosphorylation is important for the proper function of PELP1 in modulating hormone-driven cell cycle progression and also for optimal E2F transactivation function. Because the expression of both PELP1 and CDKs is deregulated in breast tumors, CDK-PELP1 interactions will have implications in breast cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.